Patent · US Active

Vaccine for treatment of tautopathy

US8945576B2 · kind B2 · utility

0Cited by
0References
7Claims
0Family size

Assignees

Inventors

Key dates

Filing dateJan 11, 2011
Grant dateFeb 3, 2015
Priority date
Expiry dateJan 11, 2031

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2799/021
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

This invention relates to a vaccine for preventing or treating tautopathy, comprising a vector, as an active ingredient, comprising a nucleic acid encoding a mutant tau protein linked to a secretion signal sequence, wherein the vaccine is capable of inducing an antibody against an (optionally phosphorylated) tau protein in a subject in a more sustained manner compared with a case where the mutant tau protein is administered directly.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.